Tocilizumab for treating COVID-19 patients (search done on 27 April 2020)
Citation: Antwi‐Amoabeng D, Kanji Z, Ford B, et al. Clinical Outcomes in COVID‐19 Patients Treated with Tocilizumab: An Individual Patient Data Systematic Review. Journal of Medical Virology. 2020 May 21.
What is this? Tocilizumab have been suggested as possible treatment for COVID-19.
In this rapid review, the authors searched for studies that reported data on individual COVID-19 patients who had received tocilizumab, sarilumab or siltuximab. They did not restrict their searches by date, type or language of publication and did their most recent search on 27 April 2020. They included 11 observational studies (total: 29 patients) from China (2 studies), France (2), Italy (2), Switzerland (1) and the USA (4).
What was found: At the time of this review, the included studies showed that although clinical improvement was reported in some patients who received tocilizumab, its effectiveness for treating COVID-19 patients is uncertain.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.